CBIO

Crescent Biopharma, Inc. Common Stock

10.81

USD

CBIO Earnings Reports

Positive Surprise Ratio

CBIO beat 29 of 38 last estimates.

76%

Next Report

Date of Next Report

Feb 09, 2026

Estimate for Q4 25 (Revenue/ EPS)

$5.10M

-$2.51

Implied change from Q3 25 (Revenue/ EPS)

+97.64%

Implied change from Q4 24 (Revenue/ EPS)

Crescent Biopharma, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, CBIO reported earnings of -1.27 USD per share (EPS) for Q3 25, beating the estimate of -2.02 USD, resulting in a 37.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.39% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 8 analysts forecast an EPS of -2.51 USD, with revenue projected to reach 5.10 million USD, implying an increase of 97.64% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were Crescent Biopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Crescent Biopharma, Inc. Common Stock reported EPS of -$1.27, beating estimates by 37.18%, and revenue of $0.00, 0% as expectations.

How did the market react to Crescent Biopharma, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 5.39%, changed from $12.43 before the earnings release to $13.10 the day after.

When is Crescent Biopharma, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 09, 2026.

What are the forecasts for Crescent Biopharma, Inc. Common Stock's next earnings report?

Based on 8 analysts, Crescent Biopharma, Inc. Common Stock is expected to report EPS of -$2.51 and revenue of $5.10M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.